Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Myelodysplastic Syndrome
100%
Cost Analysis
100%
Transfusion Support
100%
Blood Product Transfusion
100%
Transfusion
40%
Blood Products
40%
Packed Red Blood Cells (pRBCs)
30%
Median Cost
20%
Random Donor Platelets
20%
Minneapolis
10%
Medical Center
10%
Disease-modifying Therapy
10%
Secondary AML
10%
Allogeneic Transplantation
10%
Baseline Data
10%
Supportive Care
10%
Blood Transfusion
10%
Long-term Support
10%
High Incidence
10%
Resource Utilization
10%
Growth Factor Therapy
10%
Platelet Transfusion
10%
Resource Cost
10%
Premedication
10%
Transfusion Reaction
10%
Phase Time
10%
Transfusion Threshold
10%
Single Donor Apheresis Platelets
10%
Special Processing
10%
Packed Red Blood Cell Transfusion
10%
Medicine and Dentistry
Cost Benefit Analysis
100%
Myelodysplastic Syndrome
100%
Blood Product
100%
Health Care Cost
60%
Acute Myelogenous Leukemia
30%
Platelet
30%
Erythrocyte
30%
Secondary Acute Myeloid Leukemia
10%
Allograft
10%
Supportive Care
10%
Blood Transfusion
10%
Erythrocyte Transfusion
10%
Thrombocyte Transfusion
10%
Donor Apheresis
10%
Blood Transfusion Reaction
10%
Premedication
10%
Growth Factor
10%
Diseases
10%
Median Follow Up
10%
Immunology and Microbiology
Blood Product
100%
Platelet
80%
Packed Red Blood Cells
80%
Growth Factor
20%
Transfusion Reactions
20%
Blood Transfusion
20%
Apheresis
20%
Allograft
20%
Biochemistry, Genetics and Molecular Biology
Blood Product
100%
Packed Red Blood Cells
80%
Platelet
80%
Transfusion Reactions
20%
Growth Factor
20%
Apheresis
20%
Blood Transfusion
20%
Pharmacology, Toxicology and Pharmaceutical Science
Myelodysplastic Syndrome
100%
Growth Factor
10%
Secondary Acute Myeloid Leukemia
10%
Blood Transfusion Reaction
10%
Diseases
10%